Werewolf Therapeutics Inc

NASDAQ HOWL

Data sourced from

and

Download Data

Werewolf Therapeutics Inc Accounts Payable Turnover Ratio 5 year CAGR for the year ending December 31, 2023

Werewolf Therapeutics Inc Accounts Payable Turnover Ratio 5 year CAGR is NA for the year ending December 31, 2023. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Werewolf Therapeutics Inc Accounts Payable Turnover Ratio for the year ending December 31, 2022 was 13.43, a 559.64% change year over year.
Werewolf Therapeutics Inc Accounts Payable Turnover Ratio for the year ending December 31, 2021 was 2.04, a 0.00% change year over year.
Werewolf Therapeutics Inc Accounts Payable Turnover Ratio for the year ending December 31, 2020 was 0.00, a 0.00% change year over year.
Werewolf Therapeutics Inc Accounts Payable Turnover Ratio for the year ending December 31, 2019 was 0.00.

NASDAQ: HOWL

Werewolf Therapeutics Inc

CEO	Dr. Daniel J. Hicklin Ph.D.
IPO Date	April 30, 2021
Location	United States
Headquarters	1030 Massachusetts Avenue, Cambridge, MA, United States, 02138
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Key trends